Interrogation of macrophage-related prognostic signatures reveals a potential immune-mediated therapy strategy by histone deacetylase inhibition in glioma

Xisen Wang, Xuya Wang, Lei Chen, Hao Ding, Jikang Fan, Jianshen Liang, Yu Zhang, Yiming Li, Yiming Zhang, Shengping Yu, Chen Zhang, Yaohua Li, Tao Li, Xuejun YangFrontiers in Oncology 2025 · DOI

TL;DR

This study identifies a set of 14 genes associated with glioma-associated macrophages (GAMs) that can predict patient prognosis. This prognostic signature points towards histone deacetylase (HDAC) inhibitors, specifically Vorinostat, as a potential therapeutic strategy to modulate the tumor microenvironment and improve outcomes in glioma.

What Problem Does This Paper Address?

Glioma, particularly glioblastoma (GBM), remains a devastating cancer with poor survival rates despite current treatments. A key challenge in understanding and treating glioma lies in the complex tumor microenvironment (TME), which is heavily infiltrated by immune cells, especially glioma-associated macrophages (GAMs). These GAMs, often polarized towards an M2-like, pro-tumorigenic state, play a significant role in tumor progression, immune suppression, and resistance to therapy. Identifying specific GAM-related markers that can predict patient outcomes and guide therapeutic interventions is crucial for developing more effective treatments.

Methods

The researchers employed a multi-pronged approach:

  • Single-cell RNA sequencing (scRNA-seq): Used to identify specific marker genes for GAMs within the glioma TME.
  • Weighted Gene Co-expression Network Analysis (WGCNA): Applied to identify gene modules strongly associated with M2 macrophage polarization.
  • Bioinformatics and Statistical Analysis:
    • Univariate and Multivariate Cox Regression, and LASSO Regression: Used to screen for prognostic genes from the intersected GAMs markers and M2 macrophage modules.
  • Consensus Clustering: To group patients based on the identified prognostic genes.
  • Gene Set Enrichment Analysis (GSEA): To understand the biological pathways enriched in different risk groups.
  • GSVA (Gene Set Variation Analysis): To assess immune cell infiltration and function.
  • TIDE (Tumor Immune Dysfunction and Exclusion) analysis: To predict immunotherapy response.
  • In vitro and In vivo Models:
    • Cell Co-culture Models: Human glioma cell lines (A172, U87MG, TJ905) were co-cultured with human monocytic leukemia cells (THP1) or mouse macrophages (RAW264.7) to study gene expression changes and the effect of Vorinostat.
  • Drug Screening: Public databases (CTRP, GDSC) were used to identify drugs correlated with the prognostic signature.
  • RT-PCR and Western Blot: To validate gene and protein expression changes.

Datasets

  • TCGA-GBM and TCGA-LGG datasets: Used for training and validation of the prognostic signature.
  • GSE84465 dataset: A single-cell RNA-seq dataset from GBM patients, used for identifying GAM marker genes.
  • CGGA dataset: Used for external validation of the prognostic signature.
  • CTRP and GDSC databases: Used for drug sensitivity analysis.

Key Insights and Ideas

  • GAMs are key prognostic indicators in glioma: The study strongly links the abundance and characteristics of GAMs to patient survival, suggesting they are not just bystanders but active drivers of glioma progression.
  • A 14-gene signature predicts glioma prognosis: The identification of a robust 14-gene signature derived from GAM-associated genes provides a powerful tool for stratifying patients and predicting outcomes.
  • HDAC inhibitors, like Vorinostat, show therapeutic potential: The prognostic signature points towards HDAC inhibitors as a promising therapeutic avenue, with Vorinostat demonstrating significant inhibitory effects on the glioma-macrophage interaction in vitro.
  • Vorinostat modulates the tumor microenvironment: The drug appears to affect the reciprocal tumorigenicity between glioma cells and macrophages, offering a novel mechanism of action beyond direct tumor cell killing.
  • Immune landscape differences between risk groups: High-risk patients exhibit distinct immune profiles, with increased M2 macrophages and altered immune signaling pathways, suggesting a more immunosuppressive TME.

Key Results

  • 14 prognostic genes identified: TREM2, GAL3ST4, AP1B1, SLA, CYBB, CD53, SLC37A2, ABI3, RIN3, SCIN, SIGLEC10, C3, PLEKHO2, and PLXDC2 were identified as key prognostic genes.
  • Prognostic model validation: The developed prognostic model demonstrated robust predictive efficacy in both training and test sets, with AUC values for 1, 3, and 5-year survival reaching up to 0.91 in the training set.
  • Vorinostat as a candidate drug: Vorinostat showed the lowest IC50 and significant inhibitory effects in co-culture models, suggesting its potential as an immune-mediated therapeutic agent.
  • Immune cell infiltration differences: High-risk patients showed higher infiltration of M2 macrophages and CD4+ T cells compared to low-risk patients.
  • Enriched pathways in high-risk group: Pathways related to "TNFα signaling via NF-κB," "Interferon gamma response," "epithelial mesenchymal transition," and "IL6-JAK-STAT3 signaling" were enriched in the high-risk group, correlating with tumor malignancy.

Limitations and Future Work

  • Limitations:
    • The study primarily relies on retrospective data and in vitro/in vivo models.
  • While TIDE analysis suggests reduced immunotherapy efficacy in high-risk groups, further validation is needed.
  • The precise mechanisms by which some of the identified genes contribute to prognosis and drug response require deeper investigation.
  • Future Work:
    • Further investigation into the role of Vorinostat and other HDAC inhibitors in combination with immunotherapy.
  • Exploring the specific interactions between the identified prognostic genes and their impact on the glioma immune microenvironment.
  • Clinical trials to validate the prognostic signature and the therapeutic efficacy of Vorinostat in glioma patients.
  • Investigating the role of other immune cells and their interactions within the TME.

Summary updated

Abstract

These findings elucidate the molecular mechanisms of GAMs in glioma, uncover the immunological landscape of the tumor microenvironment, and identify potential therapeutic targets and drug action mechanisms.
BibTeX
@inproceedings{wang2025interrogation,
  author = {Xisen Wang and Xuya Wang and Lei Chen and Hao Ding and Jikang Fan and Jianshen Liang and Yu Zhang and Yiming Li and Yiming Zhang and Shengping Yu and Chen Zhang and Yaohua Li and Tao Li and Xuejun Yang},
  title = {{Interrogation of macrophage-related prognostic signatures reveals a potential immune-mediated therapy strategy by histone deacetylase inhibition in glioma}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2025.1554845},
}
Figure